Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas
Journal
Journal of Cancer Research and Clinical Oncology
ISSN
0171-5216
1432-1335
Date Issued
2022
Author(s)
Rodriguez-Cid, Jeronimo Rafael
Juarez-Vignon Whaley, Juan José
Sánchez-Domínguez, Gisela
Guzmán-Casta, Jordi
Carrasco-CaraChards, Sonia
Guzmán-Huesca, Jorge
Riera-Sala, Rodrigo
Sánchez-Ríos, Carla Paola
Cruz-Zermeño, Mayte
Seidman-Sorsby, Alec
Rodríguez-Zea, Ivan de Jesús
Alatorre-Alexander, Jorge Arturo
Martínez-Barrera, Luis Manuel
Santillán-Doherty, Patricio Javier
Godina-Flores, Aminadab
Imaz-Olguin, Victoria
Sosa-Sánchez, Ricardo
Green-Renner, Dan
Type
text::journal::journal article
Abstract
Purpose: Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios. Our goal is to provide insights of a three-drug chemotherapy regimen improving patient survival compared to standard regimens. Methods: Retrospective cohort analysis of patients diagnosed with unresectable/advanced primary thoracic sarcoma divided between primary pulmonary sarcomas (PPS) and chest wall sarcomas (CWS) comparing chemotherapeutical regimens efficacy. Not true soft tissue sarcomas (STS) for PPS were excluded from the analysis. Univariate and multivariate analysis performed via Cox-regression model. Progression-free survival (PFS) and overall survival (OS) analysis via Kaplan–Meier with hazard ratio (HR) obtained via Mantel–Haenszel or log rank.